"The approval of HEMGENIX reflects groundbreaking science in delivering a medicine that we believe can transform the treatment options for both the people living with haemophilia B and the healthcare professionals who treat them,” said Dr Andrew Nash, senior vice president, head of research and chief scientific officer at CSL. …
Australian patients now one step closer to accessing CSL's one-time gene therapy
March 21, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News